1266741-05-2

Basic information

• Product Name: Deferasirox Methyl Ester
• Synonyms: Deferasirox Methyl Ester
• CAS NO: 1266741-05-2
• Molecular Weight: 387.395
• Mol File: 1266741-05-2.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: Deferasirox Methyl Ester(CAS DataBase Reference)
• NIST Chemistry Reference: Deferasirox Methyl Ester(1266741-05-2)
• EPA Substance Registry System: Deferasirox Methyl Ester(1266741-05-2)

Safety Data

• Hazardous Substances Data: 1266741-05-2(Hazardous Substances Data)

Usage

General Description

Deferasirox Methyl Ester, also known as deferasirox pentyl ester, is a chemical compound that is a derivative of the iron chelator deferasirox. It is a lipophilic molecule that is designed to improve the oral bioavailability of deferasirox, which is used to treat iron overload in patients who have received multiple blood transfusions. Deferasirox Methyl Ester is thought to have similar iron chelation properties to deferasirox, but with improved solubility and bioavailability. It is being studied as a potential alternative treatment for patients who have difficulty tolerating the oral or intravenous administration of deferasirox. Overall, Deferasirox Methyl Ester may offer a promising option for the management of iron overload in certain patient populations.

Upstream product

• 75-75-2 methanesulfonic acid 
• 201530-41-8 deferasirox 
• 1642597-20-3 methyl 4-(3,5-dibromo-1H-1,2,4-triazol-1-yl)-benzoate 
• 269409-97-4 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol 
• 1218-69-5 2-(2-hydroxyphenyl)-4H-benzo[e][1,3]oxazin-4-one 
• 4510-12-7 methyl 4-hydrazinobenzoate 
• 67-56-1 methanol 
• 69-72-7 salicylic acid 
• 65-45-2 salicylamide 

Downstream Products

• 201530-41-8 deferasirox 
• 1414867-91-6 4-(5-(2-((4-boronobenzyl)oxy)phenyl)-3-(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl)benzoic acid 
• 1414867-92-7 4-(3-(2-hydroxyphenyl)-5-(2-((4-(3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborol-2-yl)benzyl)oxy)phenyl)-1H-1,2,4-triazol-1-yl)benzoic acid 
• 1414867-90-5 methyl 4-(3-(2-hydroxyphenyl)-5-(2-((4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)oxy)phenyl)-1H-1,2,4-triazol-1-yl)benzoate 

Relevant articles and documents

In vitrostudies of deferasirox derivatives as potential organelle-targeting traceable anti-cancer therapeutics

We report here strategic functionalization of the FDA approved chelator deferasirox (1) in an effort to produce organelle-targeting iron chelators with enhanced activity against A549 lung cancer cells. Derivative 8 was found to have improved antiproliferative activity relative to 1. Fluorescent cell imaging revealed that compound 8 preferentially localises within the lysosome.

Excitation Wavelength Dependent Fluorescence of an ESIPT Triazole Derivative for Amine Sensing and Anti-Counterfeiting Applications

Excitation wavelength dependent (Ex-De) emission materials have potential applications in anti-counterfeiting labels and bioimaging. Nevertheless, few purely organic chromophores are used in these areas. In this study, multiple excited states were incorporated into a molecule that was excited state intramolecular proton transfer (ESIPT) active, with the goal of manipulating the relaxation pathways of the excited states. The triazole derivative exhibits Ex-De photoluminescence (PL), and the maximum PL wavelength is located at 526 nm and 593 nm under a series of excitation wavelengths. Spectral identification indicates that the excimer and ESIPT processes are responsible for the green (526 nm) and orange (593 nm) fluorescence, respectively. Importantly, the quick response code and test strip prepared with this triazole derivative can be used for anti-counterfeiting and food spoilage detection applications, respectively. This research opens the door for developing novel Ex-De materials for anti-counterfeiting purposes.

IRON COMPLEXING AGENT AND USES THEREOF IN THE TREATMENT AND PREVENTION OF COLORECTAL CANCER

A complex comprising a non-absorbable portion attached to an iron chelator moiety, a composition comprising the complex and the use of the complex in the treatment of colorectal cancer. In one embodiment the non-absorbable portion is a polymer such as a polysaccharide, including chitosan, chitin, cellulose or pectin. In one embodiment the iron chelator moiety comprises at least one functional group selected from catechol, hydroxamate or carboxylate, or any combination thereof.